Published in PLoS One on April 13, 2015
HIV-1, methamphetamine and astrocytes at neuroinflammatory Crossroads. Front Microbiol (2015) 0.80
Metabolic and Inflammatory Adaptation of Reactive Astrocytes: Role of PPARs. Mol Neurobiol (2016) 0.78
Statins Inhibit Fibrillary β-Amyloid Induced Inflammation in a Model of the Human Blood Brain Barrier. PLoS One (2016) 0.76
Effects of Ranolazine on Astrocytes and Neurons in Primary Culture. PLoS One (2016) 0.75
Metabolic changes and inflammation in cultured astrocytes from the 5xFAD mouse model of Alzheimer's disease: Alleviation by pantethine. PLoS One (2017) 0.75
A simplification of the protein assay method of Lowry et al. which is more generally applicable. Anal Biochem (1977) 36.95
Global prevalence of dementia: a Delphi consensus study. Lancet (2005) 23.30
The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature (1998) 13.58
Astrocytes: biology and pathology. Acta Neuropathol (2009) 8.43
The endogenous cannabinoid system controls extinction of aversive memories. Nature (2002) 7.19
Production of reactive oxygen species by mitochondria: central role of complex III. J Biol Chem (2003) 5.04
Inflammation in neurodegenerative disease--a double-edged sword. Neuron (2002) 4.95
Alzheimer's disease: genotypes, phenotypes, and treatments. Science (1997) 3.72
Cytokines and acute neurodegeneration. Nat Rev Neurosci (2001) 3.70
Mitochondrial dysfunction in cardiac disease: ischemia--reperfusion, aging, and heart failure. J Mol Cell Cardiol (2001) 3.01
Inflammatory processes in Alzheimer's disease. J Neuroimmunol (2007) 2.91
Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat Rev Immunol (2005) 2.82
Mitochondrial manganese superoxide dismutase prevents neural apoptosis and reduces ischemic brain injury: suppression of peroxynitrite production, lipid peroxidation, and mitochondrial dysfunction. J Neurosci (1998) 2.65
Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci U S A (1998) 2.48
Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J Neurosci (2005) 2.31
Increased F2-isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidation in vivo. FASEB J (1998) 1.89
Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists. Front Biosci (2008) 1.88
Reduction in mitochondrial superoxide dismutase modulates Alzheimer's disease-like pathology and accelerates the onset of behavioral changes in human amyloid precursor protein transgenic mice. J Neurosci (2006) 1.69
Modulating the endocannabinoid system in human health and disease--successes and failures. FEBS J (2013) 1.59
Inflammation, anti-inflammatory agents and Alzheimer disease: the last 12 years. J Alzheimers Dis (2006) 1.58
Astrocytes: implications for neuroinflammatory pathogenesis of Alzheimer's disease. Curr Alzheimer Res (2011) 1.58
Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation. J Neuroinflammation (2005) 1.57
Inflammation in central nervous system injury. Philos Trans R Soc Lond B Biol Sci (2003) 1.56
Efficient reversal of Alzheimer's disease fibril formation and elimination of neurotoxicity by a small molecule. Proc Natl Acad Sci U S A (2004) 1.53
Synthetic cannabinoid WIN55,212-2 inhibits generation of inflammatory mediators by IL-1beta-stimulated human astrocytes. Glia (2005) 1.49
Reduction of oxidative stress, amyloid deposition, and memory deficit by manganese superoxide dismutase overexpression in a transgenic mouse model of Alzheimer's disease. FASEB J (2009) 1.47
The endocannabinoid system and cancer: therapeutic implication. Br J Pharmacol (2011) 1.46
Cannabinoids ablate release of TNFalpha in rat microglial cells stimulated with lypopolysaccharide. Glia (2003) 1.44
Mitochondrial defects in cardiomyopathy and neuromuscular disease. Am Heart J (2000) 1.44
A neuronal model of Alzheimer's disease: an insight into the mechanisms of oxidative stress-mediated mitochondrial injury. Neuroscience (2008) 1.43
Interleukin-1 in the genesis and progression of and risk for development of neuronal degeneration in Alzheimer's disease. J Leukoc Biol (2002) 1.38
Delta9-tetrahydrocannabinol induces apoptosis in C6 glioma cells. FEBS Lett (1998) 1.37
PPARgamma agonists as therapeutics for the treatment of Alzheimer's disease. Neurotherapeutics (2008) 1.36
Cannabinoid signaling in glial cells. Glia (2004) 1.35
Regulation of inflammatory response in neural cells in vitro by thiadiazolidinones derivatives through peroxisome proliferator-activated receptor gamma activation. J Biol Chem (2005) 1.34
Evidence of oxidative stress in Alzheimer's disease brain and antioxidant therapy: lights and shadows. Ann N Y Acad Sci (2008) 1.32
Anti-tumoral action of cannabinoids on hepatocellular carcinoma: role of AMPK-dependent activation of autophagy. Cell Death Differ (2011) 1.32
Cannabinoids inhibit LPS-inducible cytokine mRNA expression in rat microglial cells. Glia (2000) 1.30
Evidence of oxidative stress and in vivo neurotoxicity of beta-amyloid in a transgenic mouse model of Alzheimer's disease: a chronic oxidative paradigm for testing antioxidant therapies in vivo. Am J Pathol (1998) 1.29
Mechanisms of cell signaling and inflammation in Alzheimer's disease. Curr Drug Targets Inflamm Allergy (2005) 1.29
Increased peroxidation and reduced antioxidant enzyme activity in Alzheimer's disease. Exp Neurol (1998) 1.27
Cannabinergic ligands. Chem Phys Lipids (2002) 1.25
The endocannabinoid system in targeting inflammatory neurodegenerative diseases. Trends Pharmacol Sci (2007) 1.23
The amyloid cascade-inflammatory hypothesis of Alzheimer disease: implications for therapy. Acta Neuropathol (2013) 1.23
The case for peripheral CB₁ receptor blockade in the treatment of visceral obesity and its cardiometabolic complications. Br J Pharmacol (2011) 1.21
Changes of some oxidative stress markers in the serum of patients with mild cognitive impairment and Alzheimer's disease. Neurosci Lett (2009) 1.20
Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on beta-amyloid-induced toxicity in PC12 cells. J Neurochem (2004) 1.20
Cannabinoids and cell fate. Pharmacol Ther (2002) 1.17
Mitochondrial failures in Alzheimer's disease. Am J Alzheimers Dis Other Demen (2005) 1.17
Prolonged oral cannabinoid administration prevents neuroinflammation, lowers β-amyloid levels and improves cognitive performance in Tg APP 2576 mice. J Neuroinflammation (2012) 1.15
PPAR Regulation of Inflammatory Signaling in CNS Diseases. PPAR Res (2008) 1.11
Neuroinflammatory perspectives on the two faces of Alzheimer's disease. J Neural Transm (Vienna) (2003) 1.10
The neuroprotective effect of cannabidiol in an in vitro model of newborn hypoxic-ischemic brain damage in mice is mediated by CB(2) and adenosine receptors. Neurobiol Dis (2009) 1.06
Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer's disease. Int J Geriatr Psychiatry (1997) 1.06
Secreted beta-amyloid precursor protein activates microglia via JNK and p38-MAPK. Neurobiol Aging (2005) 1.06
Human astrocytes: secretome profiles of cytokines and chemokines. PLoS One (2014) 1.05
Detailed analysis of inflammatory and neuromodulatory cytokine secretion from human NT2 astrocytes using multiplex bead array. Neurochem Int (2011) 1.04
Estradiol or genistein prevent Alzheimer's disease-associated inflammation correlating with an increase PPAR gamma expression in cultured astrocytes. Brain Res (2009) 1.04
PPARgamma agonist curcumin reduces the amyloid-beta-stimulated inflammatory responses in primary astrocytes. J Alzheimers Dis (2010) 1.03
Peroxisome proliferator-activated receptor gamma (PPAR-γ) and neurodegenerative disorders. Mol Neurobiol (2012) 1.01
Contributions of endocannabinoid signaling to psychiatric disorders in humans: genetic and biochemical evidence. Neuroscience (2011) 1.01
Localization of the peroxisome proliferator-activated receptor in the brain. Neuroreport (1994) 1.00
Human-like rodent amyloid-beta-peptide determines Alzheimer pathology in aged wild-type Octodon degu. Neurobiol Aging (2004) 1.00
Palmitoylethanolamide counteracts reactive astrogliosis induced by β-amyloid peptide. J Cell Mol Med (2011) 0.99
The marijuana component cannabidiol inhibits beta-amyloid-induced tau protein hyperphosphorylation through Wnt/beta-catenin pathway rescue in PC12 cells. J Mol Med (Berl) (2005) 0.99
Cannabidiol in vivo blunts beta-amyloid induced neuroinflammation by suppressing IL-1beta and iNOS expression. Br J Pharmacol (2007) 0.98
Cannabinoids protect astrocytes from ceramide-induced apoptosis through the phosphatidylinositol 3-kinase/protein kinase B pathway. J Biol Chem (2002) 0.98
Cannabidiol reduces Aβ-induced neuroinflammation and promotes hippocampal neurogenesis through PPARγ involvement. PLoS One (2011) 0.97
Inflammatory activation of human brain endothelial cells by hypoxic astrocytes in vitro is mediated by IL-1beta. J Cereb Blood Flow Metab (2000) 0.97
Anandamide and noladin ether prevent neurotoxicity of the human amyloid-beta peptide. Neurosci Lett (2002) 0.97
Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: relevance to Alzheimer's disease. Mol Pharmacol (2011) 0.96
Understanding risk factors for Alzheimer's disease: interplay of neuroinflammation, connexin-based communication and oxidative stress. Arch Med Res (2012) 0.95
Cannabinoids protect cells from oxidative cell death: a receptor-independent mechanism. J Pharmacol Exp Ther (2000) 0.95
Activation of PARP by oxidative stress induced by β-amyloid: implications for Alzheimer's disease. Neurochem Res (2012) 0.95
WIN55212-2 attenuates amyloid-beta-induced neuroinflammation in rats through activation of cannabinoid receptors and PPAR-γ pathway. Neuropharmacology (2012) 0.94
Cannabinoids: a new group of agonists of PPARs. PPAR Res (2007) 0.94
Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia. Psychopharmacology (Berl) (2006) 0.93
Cannabinoids for the treatment of dementia. Cochrane Database Syst Rev (2009) 0.91
Exposure to inflammatory cytokines IL-1β and TNFα induces compromise and death of astrocytes; implications for chronic neuroinflammation. PLoS One (2013) 0.90
Oestradiol or genistein rescues neurons from amyloid beta-induced cell death by inhibiting activation of p38. Aging Cell (2007) 0.89
Non-THC cannabinoids inhibit prostate carcinoma growth in vitro and in vivo: pro-apoptotic effects and underlying mechanisms. Br J Pharmacol (2013) 0.89
Sugammadex, a neuromuscular blockade reversal agent, causes neuronal apoptosis in primary cultures. Int J Med Sci (2013) 0.88
Molecular and cellular mediators of Alzheimer's disease inflammation. J Alzheimers Dis (2001) 0.88
Abeta mediated diminution of MTT reduction--an artefact of single cell culture? PLoS One (2008) 0.88
Cannabinoid receptor activation and elevated cyclic AMP reduce glutamate neurotoxicity. Eur J Neurosci (2001) 0.87
Astrocytes protect neurons from Aβ1-42 peptide-induced neurotoxicity increasing TFAM and PGC-1 and decreasing PPAR-γ and SIRT-1. Int J Med Sci (2015) 0.82
Recruitment of a heparan sulfate subunit to the interleukin-1 receptor complex. Regulation by fibronectin attachment. J Biol Chem (1999) 0.82
Age-related changes in brain extracellular space affect processing of amyloid-β peptides in Alzheimer's disease. J Alzheimers Dis (2013) 0.79
Systematic review of the literature on clinical and experimental trials on the antitumor effects of cannabinoids in gliomas. J Neurooncol (2013) 0.77
[Oxidative stress and Alzheimer's disease]. Rev Neurol (2006) 0.76
Evaluation of anti-invasion effect of cannabinoids on human hepatocarcinoma cells. Toxicol Mech Methods (2012) 0.76
Neuronal Effects of Sugammadex in combination with Rocuronium or Vecuronium. Int J Med Sci (2017) 0.75